Меню
Набор скоро начнётся NCT07471763

Prospective Lifespan Cohort of Myocardial Infarction

— Наблюдательное Acute Myocardial Infarction (AMI) Stable Angina Unstable Angina

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: Acute Myocardial Infarction (AMI), Stable Angina, Unstable Angina. Базовые параметры: 18 лет — 74 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Prospective Lifespan Cohort Study of Myocardial Infarction for Building an Integrated Multidimensional Database and Developing an Artificial Intelligence- and Multi-omics-Driven Precision Prevention and Control System

Обзор

This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management. The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up. The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.

Первичные конечные точки

  • Rate of all-cause mortality [Срок оценки: From enrollment to the end of study follow-up, up to 5 years]
Вторичные конечные точки (7)
  • Rate of cardiovascular death [Срок оценки: From enrollment to the end of study follow-up, up to 5 years]
  • Rate of recurrent myocardial infarction [Срок оценки: From enrollment to the end of study follow-up, up to 5 years]
  • Rate of readmission due to heart failure [Срок оценки: From enrollment to the end of study follow-up, up to 5 years]
  • Rate of target vessel or non-target vessel revascularization [Срок оценки: From enrollment to the end of study follow-up, up to 5 years]
  • Rate of stroke [Срок оценки: From enrollment to the end of study follow-up, up to 5 years]
  • Rate of definite or probable stent thrombosis [Срок оценки: From enrollment to the end of study follow-up, up to 5 years]
  • Rate of severe bleeding [Срок оценки: From enrollment to the end of study follow-up, up to 5 years]

Критерии участия

Критерии включения

Age 18 to 74 years

Diagnosed with stable angina, unstable angina, or acute myocardial infarction

For acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized

Diagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction

Willing to participate and able to provide written informed consent

Able to complete baseline assessment, biospecimen collection, and long-term follow-up

Критерии исключения

End-stage malignant tumor with expected survival of less than 1 year

Severe hepatic or renal dysfunction (estimated glomerular filtration rate <30 mL/min/1.73 m² or Child-Pugh class C)

Active autoimmune disease or long-term use of immunosuppressive agents

Pregnant or breastfeeding women

Inability to provide informed consent or severe cognitive impairment

Previous participation in another clinical study that may conflict with this project

Any other condition considered by the investigators to make participation inappropriate

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Китай · 1 центр
  • Fuzhou University Affiliated Provincial Hospital — Фучжоу

Идентификаторы

NCT: NCT07471763 · K2026-03-001

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗